Jazz Pharmaceuticals plc JAZZ

NAS: JAZZ | ISIN: IE00B4Q5ZN47   14/11/2024
124,27 USD (-2,65%)
(-2,65%)   14/11/2024

9 september 2024 · Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024 · Persbericht

5 september 2024 · Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024 · Persbericht

4 september 2024 · Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases · Persbericht

3 september 2024 · Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases · Persbericht

22 augustus 2024 · Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies · Persbericht

21 augustus 2024 · Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences · Persbericht

31 juli 2024 · Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance · Persbericht

25 juli 2024 · Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting · Persbericht

22 juli 2024 · Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026 · Persbericht

17 juli 2024 · Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024 · Persbericht

9 juli 2024 · Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer · Persbericht

20 juni 2024 · Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor · Persbericht

1 juni 2024 · Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 · Persbericht

30 mei 2024 · Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 · Persbericht

29 mei 2024 · Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences · Persbericht

29 mei 2024 · Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer · Persbericht

22 mei 2024 · Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism · Persbericht

1 mei 2024 · Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference · Persbericht

1 mei 2024 · Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance · Persbericht

24 april 2024 · Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 · Persbericht

Mijn selecties